Balyasny Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Balyasny Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-852,828	Closed	-$33.9M	–	3069
2026 Q1	$33.9M	Buy	852,828 +384,013	+82%	+$9.82M	0.04%	488
2025 Q4	$11.7M	Sell	468,815 -336,796	-42%	-$8.53M	0.01%	953
2025 Q3	$19.5M	Sell	805,611 -415,999	-34%	-$7.39M	0.02%	729
2025 Q2	$16.1M	Buy	+1,221,610	New	+$15.5M	0.02%	756
2025 Q1	–	Sell	-175,428	Closed	-$2.94M	–	2854
2024 Q4	$2.94M	Sell	175,428 -505,993	-74%	-$8.38M	﹤0.01%	1520
2024 Q3	$10.9M	Sell	681,421 -341,701	-33%	-$4.19M	0.02%	903
2024 Q2	$9.24M	Buy	1,023,122 +768,676	+302%	+$7.29M	0.02%	920
2024 Q1	$2.88M	Buy	+254,446	New	+$2.41M	0.01%	1424

Balyasny Asset Management's CNTA Position: Q2 2026 in Review

Balyasny Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 852,828 shares — an estimated $33.9M sold.

Balyasny Asset Management first reported a position in CNTA in Q1 2024 and held it in 8 quarters. The position peaked at $33.9M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Balyasny Asset Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Balyasny Asset Management sold 852,828 Centessa Pharmaceuticals shares in Q2 2026, an estimated $33.9M.
Balyasny Asset Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Balyasny Asset Management's Centessa Pharmaceuticals position peaked at $33.9M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.